Innovation in a hurry: China biotechs see a fast track to global stage – survey
BioCentury, BayHelix survey finds China biotechs expect to fund their own growth but will need global deals to accelerate at a pace that meets their ambition
The Chinese biopharma landscape in five years will see a majority of the money magnet companies commanding innovation, with first-in-class targets filling their pipelines and innovative biologics outpacing biosimilars for revenue. But while the ecosystem may depend on the West for in-licensing assets and reaching a global market, it will be heavily reliant on its own investors to finance the growth, and neither investors, companies nor their employees are waiting for the West to adjust to the Chinese appetite for rapid success.
Those are the conclusions from a survey of 29 Chinese biopharmas conducted by BioCentury and BayHelix, and comments by panelists at the BioCentury-BayHelix 7th China Healthcare Summit in a Nov. 9 session titled “Where is the ‘Bridge to Innovation’ Headed.”...